Loading organizations...

Cadent Therapeutics is a technology company.
Cadent Therapeutics developed precision neuroscience medicines aimed at restoring cognitive, mood, and movement functions. The company engineered novel therapeutics by modulating brain rhythms and targeting specific ion channels and the NMDA receptor. Its drug discovery programs addressed a broad range of central nervous system disorders.
Cadent Therapeutics formed in 2017 from the merger of Luc Therapeutics and Ataxion. The company's scientific lineage began with Mnemosyne Pharmaceuticals, founded in 2010 by former Pfizer scientists Frank Menniti and Bert Chenard, alongside entrepreneur Kollol Pal. This team's extensive pharmaceutical expertise fueled drug discovery programs targeting the NMDA receptor for central nervous system disorders, establishing an innovative therapeutic platform.
Cadent Therapeutics designed its therapies for individuals suffering from cognitive, mood, and movement disorders where brain rhythm dysregulation played a role. The company's vision centered on creating a pipeline of novel small molecule therapeutics that precisely modulate brain activity, aiming to significantly improve the lives of patients with difficult-to-treat neurological and psychiatric conditions.
Cadent Therapeutics has raised $61.3M across 4 funding rounds.
Cadent Therapeutics has raised $61.3M in total across 4 funding rounds.
Cadent Therapeutics was a clinical-stage biopharmaceutical company developing precision neuroscience therapies to treat movement disorders like essential tremor and spinocerebellar ataxia, as well as cognitive impairments such as schizophrenia and treatment-resistant depression.[1][2][3] It targeted unmet needs by combining target specificity, patient selection, drug design, and novel endpoints to create first-in-class molecules, including positive allosteric modulators and a negative allosteric modulator licensed to Novartis.[1][3] The company served patients with serious neurological diseases, solving problems of irregular neuronal firing through brain rhythm modulation, and raised $55M before its acquisition by Novartis in 2021 for up to $770M.[4][6]
Founded in 2017, Cadent Therapeutics emerged from neuroscience research focused on modulating ion channels to restore cognitive and motor function.[4][7] Key leadership included Michael Curtis, Ph.D., as initial President and CEO, later transitioning to President and Head of R&D, and Jodie Morrison appointed CEO in 2019 with over 20 years in biopharma.[3] Early traction came via a $40M Series B in November 2018 from investors like Atlas Venture, Novartis Institutes for Biomedical Research, Qiming Venture Partners, and others, funding its pipeline of allosteric modulators.[1][3] A pivotal 2015 licensing deal with Novartis for MIJ821 (now in Phase 1 for treatment-resistant depression) set the stage for deeper collaboration.[2][3]
Cadent rode the wave of precision neuroscience, addressing neuropsychiatric disorders with limited treatments amid rising demand for brain-targeted therapies.[2] Its timing aligned with advances in allosteric modulation and ion channel science, filling gaps in movement (e.g., essential tremor affecting millions) and cognitive disorders where systemic drugs fall short.[1][5][6] Market forces like big pharma's neuroscience push—evident in Novartis' commitment—favored Cadent, influencing the ecosystem by validating small-molecule innovators and accelerating Phase II assets into larger portfolios.[2][4] The 2021 acquisition exemplified how startups shape biopharma pipelines, transferring programs like CAD-1883 for movement disorders and schizophrenia candidates to global scale.[2][6]
Post-acquisition, Cadent's assets integrated into Novartis' neuroscience portfolio, with MIJ821 advancing in Phase 1 for depression and CAD-1883 explored for movement disorders—likely driving near-term milestones up to $560M.[2][6] Trends like targeted neuromodulation and AI-aided drug design will shape their legacy, potentially yielding approvals in underserved areas. Novartis' influence could evolve these into transformative therapies, echoing Cadent's mission to restore brain function and underscoring biotech's role in precision medicine breakthroughs.[2][4]
Cadent Therapeutics has raised $61.3M in total across 4 funding rounds.
Cadent Therapeutics's investors include Atlas Venture, Cowen Healthcare Investments, 11.2 Capital, AME Cloud Ventures, Autotech Ventures, Bessemer Venture Partners, Cota Capital, Greylock, Hardware Club, M34 Capital, NEO, Next47.
Cadent Therapeutics has raised $61.3M across 4 funding rounds. Most recently, it raised $15.0M Series B in April 2020.